發(fā)布時(shí)間：2018-04-03 02:06

  本文選題：皮質(zhì)醇增多癥　切入點(diǎn)：脆性組氨酸三聯(lián)體　出處：《重慶醫(yī)學(xué)》2016年05期

【摘要】：目的探討皮質(zhì)醇增多癥腎上腺皮質(zhì)不同病變中脆性組氨酸三聯(lián)體(FHIT)、Ki-67及增殖細(xì)胞核抗原(PCNA)的表達(dá)水平及其在鑒別診斷中的作用。方法應(yīng)用免疫組織化學(xué)方法檢測(cè)49例皮質(zhì)醇增多癥腎上腺皮質(zhì)病變(腺癌14例、腺瘤26例、皮質(zhì)增生9例)患者FHIT、Ki-67及PCNA的表達(dá)。結(jié)果 FHIT在腎上腺皮質(zhì)增生表達(dá)最高,腺瘤次之,腺癌最低(分別為100.00%、96.15%、42.86%);Ki-67與PCNA在腎上腺皮質(zhì)腺癌的表達(dá)最高,腺瘤次之,皮質(zhì)增生最低(分別為85.71%、7.69%、0和100.00%、96.15%、77.78%)。FHIT、Ki-67及PCNA在皮質(zhì)醇增多癥腎上腺皮質(zhì)病變中的表達(dá)兩兩相關(guān),其中FHIT與Ki-67表達(dá)呈負(fù)相關(guān)(r=-0.718,P=0.00),FHIT與PCNA表達(dá)呈負(fù)相關(guān)(r=-0.449,P=0.001),Ki-67與PCNA表達(dá)呈正相關(guān)(r=0.387,P=0.006)。聯(lián)合檢測(cè)FHIT、Ki67及PCNA結(jié)果顯示,腺癌表現(xiàn)為FHIT陰性或弱陽(yáng)性、Ki-67強(qiáng)陽(yáng)性、PCNA強(qiáng)陽(yáng)性;腺瘤表現(xiàn)為FHIT陽(yáng)性、Ki-67陽(yáng)性、PCNA陽(yáng)性;皮質(zhì)增生表現(xiàn)為FHIT強(qiáng)陽(yáng)性、Ki-67陰性、PCNA陰性。結(jié)論聯(lián)合檢測(cè)FHIT、Ki-67及PCNA對(duì)腎上腺皮質(zhì)腺癌、腺瘤及增生的鑒別診斷具有重要的價(jià)值。
[Abstract]:Objective to investigate the expression level of FHITK Ki-67 and proliferating cell nuclear antigen (PCNA) in different lesions of adrenal cortex in patients with corticostosis and their role in differential diagnosis.Methods Immunohistochemical method was used to detect the expression of FHITKi-67 and PCNA in 49 patients with adrenal cortical lesions (adenocarcinoma 14, adenoma 26, cortical hyperplasia 9).Results the expression of FHIT was the highest in adrenocortical hyperplasia, followed by adenoma, and the lowest in adenocarcinoma (100.00,96.15). Ki-67 and PCNA were the highest in adrenal cortical adenocarcinoma, followed by adenoma.鐨川澧炵敓鏈，

本文編號(hào)：1703125